Macrocyclic compounds and methods of treatment
The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
1. A method of treating a subject suffering from a cell proliferation related disorder or disease, wherein the subject has been identified as in need of treatment for a cell proliferation related disorder or disease, comprising administering to said subject in need thereof; an effective amount of a compound or pharmaceutical composition of formula I, such that said subject is treated for said disorder:
wherein:
each R is independently H or optionally substituted alkyl;
each R 1 is independently or optionally substituted alkyl;
each R 2 is independently H, optionally substituted alkyl, or C(O)R;
each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;
each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;
the disorder is selected from one or more of the group consisting of brain cancer, mesothelioma, kidney cancer, bladder cancer, prostate cancer, cutaneous T-cell lymphoma, an angiogenesis disorder, and ovarian cancer;
and pharmaceutically acceptable salts thereof.
2. The method of claim 1 , wherein the compound of formula I is one of Compounds 1-8.
3. The method of claim 1 , wherein the disorder is an angiogenesis disorder.
4. The method of claim 1 , wherein the subject is a mammal.
5. The method of claim 1 wherein the subject is a primate or human.
6. The method of claim 1 , wherein the compound of formula I is administered intravenously, intramuscularly, subcutaneously, intracerebroventricularly, orally or topically.
7. The method of claim 1 , wherein the compound of formula I is administered alone or in combination with one or more other therapeutics.
8. The method of claim 7 , wherein the additional therapeutic agent is an anti-cancer agent, chemotherapeutic agent, an anti-angiogenesis agent, cytotoxic agent, or an anti-proliferation agent.
9. A method of treating an histone deacetylase (HDAC) mediated disease or disorder, comprising administering to said subject in need thereof, an effective amount of any of Compounds 1-8, and pharmaceutically acceptable salts thereof;
wherein the disorder is selected from one or more of the group consisting of brain cancer, mesothelioma, kidney cancer, bladder cancer, prostate cancer, cutaneous T-cell lymphoma, an angiogenesis disorder, and ovarian cancer.
10. A method for treating memory loss, inducing neurogenesis, enhancing memory retention, enhancing memory formation, increasing synaptic potential or transmission, or increasing long term potentiation (LIP) in a subject, comprising administering to said subject in need thereof, an effective amount of a compound of formula (I) in claim 1 , or pharmaceutically acceptable salts thereof:
wherein:
each R is independently H or optionally substituted alkyl;
each R 1 is independently H, or optionally substituted alkyl;
each R 2 is independently H, optionally substituted alkyl, or C(O)R;
each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;
each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR.
11. A method for treating diseases and disorders associated with stem cell fate and that are affected by cell differentiation, dedifferentiation or transdifferentiation in a subject, comprising administering to said subject in need thereof, an effective amount of a compound of formula (I) in claim 1 , or pharmaceutically acceptable salts thereof:
wherein:
each R is independently H or optionally substituted alkyl;
each R 1 is independently H, or optionally substituted alkyl;
each R 2 is independently H, optionally substituted alkyl, or C(O)R;
each R 3 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR;
each R 4 is independently H, optionally substituted alkyl, C(O)OR, or C(O)NRR.
12. The method of claim 1 , wherein R 3 and R 4 are H.
13. The method of claim 1 , R 1 is isopropyl.
14. The method of claim 1 , wherein the compound is largazole.
15. The method of claim 1 , wherein R 2 is alkyl.
16. The method of claim 1 , wherein R 2 is alkylC(O)—.